Spiro Rombotis
2023
In 2023, Spiro Rombotis earned a total compensation of $661K as President and Chief Executive Officer at Cyclacel Pharmaceuticals, a 13% decrease compared to previous year.
Compensation breakdown
| Option Awards | $48,581 |
|---|---|
| Salary | $560,131 |
| Other | $52,337 |
| Total | $661,049 |
Rombotis received $560.1K in salary, accounting for 85% of the total pay in 2023.
Rombotis also received $48.6K in option awards and $52.3K in other compensation.
Rankings
In 2023, Spiro Rombotis' compensation ranked 1,704th out of 3,006 executives tracked by ExecPay. In other words, Rombotis earned more than 43.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,704 out of 3,006 | 43rd |
Division Manufacturing | 993 out of 1,650 | 40th |
Major group Chemicals And Allied Products | 633 out of 918 | 31st |
Industry group Drugs | 617 out of 881 | 30th |
Industry Pharmaceutical Preparations | 441 out of 637 | 31st |
Source: SEC filing on May 7, 2024.
Rombotis' colleagues
We found two more compensation records of executives who worked with Spiro Rombotis at Cyclacel Pharmaceuticals in 2023.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2019 pay jumps 35% to $1M
May 12, 2020